更新于：2024-05-11

Metoclopramide Hydrochloride

盐酸甲氧氯普胺

更新于：2024-05-11

概要

概要

基本信息

简介甲氧氯普胺是一种多巴胺-2（D2）拮抗剂的小分子药物。用于治疗胃食管反流病（GERD）和急性或复发性糖尿病胃轻瘫（胃淤滞）等疾病，该药最初由赛诺菲开发，于1967年3月首次在日本批准使用。是一种可用于口服和注射的药物。

药物类型

小分子化药

别名

2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide、2-methoxy-5-chloroprocainamide、4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide

+ [31]

靶点

DRDs

作用机制

DRDs拮抗剂(多巴胺受体家族拮抗剂)

治疗领域

神经系统疾病消化系统疾病内分泌与代谢疾病+ [3]

在研适应症

药物引起的恶心和呕吐放疗引起的恶心和呕吐呕吐+ [4]

非在研适应症

化疗引起的恶心和呕吐危重病术后恶心呕吐

原研机构

Sanofi

在研机构

Nichi-Iko Pharmaceutical Co., Ltd.Bridgewest Perth Pharma Pty Ltd.

Evoke Pharma, Inc.

+ [3]

非在研机构

Hikma Pharmaceuticals USA, Inc.

Millennium Pharmaceuticals, Inc.

Salix Pharmaceuticals, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

日本 (1967-03-25),

食欲减退恶心和呕吐

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C14H26Cl3N3O3

InChIKeyIRQVJPHZDYMXNW-UHFFFAOYSA-N

CAS号5581-45-3

关联

219

项与盐酸甲氧氯普胺相关的临床试验

NCT06379217 / Not yet recruiting临床1期

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gonadotropin Releasing Hormone Receptor (GRPR)) between the start and after the completion of radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).

开始日期2024-06-18

申办/合作机构

Novartis Pharmaceuticals Corp.

CTRI/2024/02/062858 / Not yet recruitingN/A

Comparison of enteral erythromycin plus intravenous Metoclopramide versus entral erythromycin alone in critically ill patient with enteral feed intolerance - NIL

开始日期2024-02-25

申办/合作机构

Eras Lucknow Medical College & Hospital Pvt Ltd.

NCT06390787 / Completed临床2/3期IIT

Enhancing Antiemetic Efficacy: A Randomized Trial of Vitamin B6 and Metoclopramide Combination Therapy Versus Traditional Regimens

This study investigates the effectiveness of combining vitamin B6 (pyridoxine) and metoclopramide compared to standard antiemetic treatments for managing nausea and vomiting. Through a prospective, randomized controlled trial involving adult patients with diverse causes of nausea and vomiting, we aim to evaluate the frequency, severity, and tolerability of the B6 and metoclopramide combination. By elucidating its comparative efficacy against established antiemetics, this research seeks to provide evidence-based guidance for clinicians in selecting optimal treatment regimens tailored to individual patient needs, ultimately enhancing the management of nausea and vomiting across various medical conditions.

开始日期2024-01-30

申办/合作机构

University of Baghdad

100 项与盐酸甲氧氯普胺相关的临床结果

登录后查看更多信息

100 项与盐酸甲氧氯普胺相关的转化医学

登录后查看更多信息

100 项与盐酸甲氧氯普胺相关的专利（医药）

登录后查看更多信息

6,128

项与盐酸甲氧氯普胺相关的文献（医药）

2024-03-01·European Journal of Hospital Pharmacy

Rare case report of moxifloxacin-induced persistent hiccups

Article

作者: Zhou, Jing ; Li, Songlong ; Wang, Fei

Moxifloxacin is a broad-spectrum antimicrobial agent that is commonly used in clinical practice. Here we report an unusual case of a patient with persistent hiccups caused by moxifloxacin. A man aged in his 40s was treated with moxifloxacin for tuberculous pleurisy. Hiccups occurred 2 hours after intravenous injection of moxifloxacin and lasted into evening. On the second day after injection, hiccups occurred again and made it difficult for him to fall asleep. The clinician ruled out gastrointestinal disease, nervous system disease, electrolyte disturbance and other factors. On assessing causality of the adverse drug reaction, the Naranjo scale for moxifloxacin was six, indicating a probable relationship of hiccups with moxifloxacin. Hiccups stopped 2 min after intramuscular injection of metoclopramide. To our knowledge, this is the first case report about moxifloxacin-induced persistent hiccups. Clinicians should be aware of the rare adverse reaction.

2024-01-01·Revista Española de Enfermedades Digestivas

OGILVIE, WHEN MEDICAL AND ENDOSCOPIC TREATMENT FAIL

Article

作者: Quiñones Castro, Raisa ; Domínguez Carbajo, Ana Belén ; González Puente, Isabel ; Borrego Rivas, Sandra

Ogilvie syndrome is a functional disorder of colonic motility that causes acute and progressive dilation, which can lead to necrosis and perforation. Early diagnosis and management are essential to avoid serious complications. The case of a patient with Ogilvie syndrome refractory to medical and endoscopic treatment that required surgery is presented. This is a 68-year-old man with decreased level of consciousness and abdominal distension for 3 days. Last bowel movement 4 days ago. The data and tests appear in table 1. We are faced with a patient with neurological alteration and hemodynamically unstable secondary to complicated Ogilvie syndrome. After admission to the ICU, where a 2.5 mg bolus of neostigmine was administered, he was transferred to the ward. Despite 250 mg of intravenous erythromycin every 6 hours together with metoclopramide every 8 hours, high doses of polyethylene glycol and daily cleansing enemas and rectal catheterization, only a brief and mild improvement is achieved. Given the failure of conservative measures, colectomy was performed, achieving complete resolution. Ogilvie syndrome is a functional disorder1 that usually associates predisposing factors that impact intestinal motility 2 ; In our case: bedridden, the use of anticholinergics, hydroelectric alteration both due to the use of antidepressants and the creation of a third space secondary to colonic dilation and severe intestinal ischemia². In one third it is resolved by early correction of the triggering factors, adding neostigmine if necessary with high rates of effectiveness¹. In our case, a second bolus of neostigmine could have been administered or even as an infusion since greater efficacy has been demonstrated in this way given its short half-life². Electrolyte imbalance is a predictor of poor response to neostigmine, a factor that was associated with our patient 3. Colonic decompression and finally surgery are reserved as a last measure, being necessary in a very small percentage as in this case 1. As a preventive measure, the administration of 29.5 g of oral polyethylene glycol per day has been effective 4. Therefore, we should suspect Ogilvie syndrome in patients with predisposing factors who present acute dilation of the colon without mechanical obstruction, and although it usually resolves with medical and endoscopic treatment, we should not delay surgery to avoid complications.

2024-01-01·Migraine Management

Nonspecific analgesics, combination analgesics, and antiemetics

Review

作者: Tassorelli, Cristina ; Pocora, Maria Magdalena ; Martinelli, Daniele

The acute treatment of migraine attacks should provide rapid, effective, and long-lasting symptom relief, causing minimal adverse effects. For this purpose, there are several specific and nonspecific acute treatments. In this chapter, we focus on molecules not specifically designed for migraines, including anti-inflammatory not specific analgesics, such as acetaminophen, acetylsalicylic acid, and other non-steroidal anti-inflammatory drugs (or COX-2 inhibitors); antinausea medications like metoclopramide or prochlorperazine, which can alleviate sickness and vomiting associated with migraines, and may also have a direct painkiller effect; combinations of simple analgesics or association of a painkiller with caffeine. This stimulant can help enhance the pain-relieving effects of some headache medications and provide its own analgesic effect; physical approaches: applying cold packs or heating pads on the forehead or neck, can help relieve migraine pain; other classes with limited to no evidence to support their use, such as intravenous corticosteroids or antiepileptic drugs as sodium valproate. Finally, we will briefly mention opioids, barbiturates, or medical cannabis, bearing in mind that their use is not recommended by current guidelines.

100

项与盐酸甲氧氯普胺相关的新闻（医药）

2024-05-06

·PRNewswire

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed1-3 The diagnosis rate can be improved by increasing routine TD screenings in people treated with antipsychotic medication4 SAN DIEGO, May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11. TD is a persistent, involuntary movement disorder associated with the use of antipsychotic medication that may be necessary to treat individuals living with mental illness, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder.1,5-7 For seven consecutive years, TD Awareness Week – which occurs each year during Mental Health Awareness Month – has brought together the mental health advocacy community and states across the country to recognize the approximately 600,000 people in the U.S. living with TD.1,2 This year, Neurocrine is joining participants of TD Awareness Week to conduct initiatives nationwide to decrease stigma, improve recognition and increase routine screenings, diagnosis and awareness of appropriate treatment of TD. "TD Awareness Week increases dialogue around the physical, social and emotional consequences the uncontrollable movements of TD can have on individuals who are trying to manage their mental health," said Josie Cooper, Executive Director of the Movement Disorders Policy Coalition. "It's important that we continue to work together to acknowledge and increase support for people living with TD and to ensure they receive the diagnosis and care they deserve." TD is a chronic condition that is unlikely to improve without treatment.1,4 The uncontrollable movements can affect one's ability to work, drive, walk, button a shirt or eat and drink and cause worry, frustration and self-consciousness.2,8-10 It is critical that people taking antipsychotic medication for mental illness be monitored by a healthcare provider for drug-induced movement disorders, such as TD.4,6 Routine screenings are essential for detection, proper diagnosis and appropriate management to help improve therapeutic outcomes.4 "The majority of people living with TD remain undiagnosed, reinforcing the importance of proactive recognition and treatment of the condition," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "We are committed to partnering with all stakeholders during TD Awareness Week and beyond to advocate for routine screenings for patients at risk for TD." The Meadows Mental Health Policy Institute, which provides nonpartisan, data-driven and program guidance to improve mental health services, released a recent report, in collaboration with Neurocrine Biosciences, highlighting the importance of measurement-based care (MBC) for people with a serious mental illness who are treated with antipsychotics. MBC involves the systematic use of validated rating scales to assess the effectiveness of treatment and make adjustments as needed to improve outcomes.11 For TD, MBC provides an effective mechanism for earlier detection and the ability to develop and routinely monitor an appropriate treatment plan for patients to help improve outcomes.11 The full report can be accessed at . The 2020 American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia recommends screening for TD at least every six months in high-risk patients and at least every 12 months for others at risk of developing TD.4 To learn more about TD, living with TD and how to treat TD, visit TalkAboutTD.com. About Tardive Dyskinesia Awareness Week Since it began in 2018, all 50 states, Washington, D.C., and various mental health advocacy organizations have recognized the first full week of May as Tardive Dyskinesia (TD) Awareness Week, which acknowledges the approximately 600,000 Americans living with TD, an involuntary movement disorder associated with taking antipsychotic medication commonly prescribed to treat mental illnesses. Participants in TD Awareness Week help to educate people across the United States on the potential physical, social and emotional consequences of TD and the importance of speaking with a healthcare provider about the occurrence and impact of the uncontrollable movements and available treatment options. As part of Neurocrine Biosciences' commitment to TD education, more information is available at Neurocrine.com/TD-Awareness, and resources are available at TalkAboutTD.com. These resources can help patients and care partners understand TD and recognize its symptoms, request support and have a conversation with their healthcare provider about ways to manage their TD, including treatment options. Healthcare professionals can also visit MIND-TD.com to learn about differential diagnosis of TD and other movement disorders. For more information, follow and join the conversation online by sharing #TDAwarenessWeek #Screen4TD. About Tardive Dyskinesia (TD) Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder, and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect approximately 600,000 people in the United States. About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie) NEUROCRINE BIOSCIENCES, NEUROCRINE and YOU DESERVE BRAVE SCIENCE, are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc. References Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176. doi:10.1007/s13311-013-0222-5 Data on file. Neurocrine Biosciences, Inc. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278. doi:10.4088/JCP.16r10832 Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Revision. American Psychiatric Association; 2023. Guy W. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health; 1976. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-148. doi:10.1016/j.ncl.2010.10.002 Task Force on Tardive Dyskinesia. Tardive dyskinesia: a task force report of the American Psychiatric Association; 1992. Boumans CE, de Mooij KJ, Koch PA, van 't Hof MA, Zitman FG. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull. 1994;20(2):339-344. doi:10.1093/schbul/20.2.339 Yassa R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989;80(1):64-67. doi:10.1111/j.1600-0447.1989.tb01301 Increasing measurement-based assessment and care for people with serious mental illness. Meadows Mental Health Policy Institute. Published January 2024. Accessed March 1, 2024. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-TD-US-1569 05/2024 SOURCE Neurocrine Biosciences, Inc.

2024-05-06

·信狐药迅

常山凯捷健GLP-1激动剂艾本那肽、轩竹生物达希替尼、贝达CDK4/6抑制剂泰贝西利提交上市申请| 新受理（4.22-5.5）

本周药品注册受理数据，分门别类呈现，一目了然。(4.22-5.5）小编收到有些用户反应，不想收到咱们每周文章的推送提醒，而有些用户又特别需要这个提醒，在小编强烈要求下，我们给力的程序员终于实现了可以关闭提醒的功能，这个绝对全网独一家喔，不想收到提醒的，只要在信狐药迅对话框内回复关键词“拒收文章提醒”，那么就可以不受推送的打扰啦!新药上市申请药品名称企业注册分类受理号艾本那肽注射液常山凯捷健生物药物研发(河北)有限公司1CXHS2400034达希替尼片轩竹生物科技股份有限公司1CXHS2400036达希替尼片轩竹生物科技股份有限公司1CXHS2400035莫米司特片赣州和美药业股份有限公司1CXHS2400033氟唑帕利胶囊江苏恒瑞医药股份有限公司2.4CXHS2400032甲磺酸阿帕替尼片江苏恒瑞医药股份有限公司2.4CXHS2400031甲磺酸阿帕替尼片江苏恒瑞医药股份有限公司2.4CXHS2400030鼻喷流感减毒活疫苗长春百克生物科技股份公司3.2CXSS2400043卡度尼利单抗注射液中山康方生物医药有限公司2.2CXSS2400042酒石酸泰贝西利胶囊贝达药业股份有限公司1CXHS2400039苹果酸司妥吉仑片上海上药信谊药厂有限公司1CXHS2400037司普奇拜单抗注射液成都康诺行生物医药科技有限公司1CXSS2400045利多卡因凝胶贴膏北京泰德制药股份有限公司2.4CXHS2400038新药临床申请药品名称企业注册分类受理号HS-10370片江苏豪森药业集团有限公司1CXHL2400420TYK-01054胶囊浙江同源康医药股份有限公司1CXHL2400419TYK-01054胶囊浙江同源康医药股份有限公司1CXHL2400418TQB3911片正大天晴药业集团南京顺欣制药有限公司1CXHL2400413TQB3911片正大天晴药业集团南京顺欣制药有限公司1CXHL2400412注射用IPG浙江仙琚制药股份有限公司2.2CXHL2400417艾司奥美拉唑镁碳酸氢钠干混悬剂(Ⅰ)海南灵康制药有限公司2.2CXHL2400416艾司奥美拉唑镁碳酸氢钠干混悬剂(Ⅰ)海南灵康制药有限公司2.2CXHL2400415TRD303溶液北京泰德制药股份有限公司2.2CXHL2400407CP006吸入粉雾剂上海新黄河制药有限公司2.3CXHL2400414甲磺酸伏美替尼片上海艾力斯医药科技股份有限公司2.4CXHL2400411羟乙磺酸达尔西利片江苏恒瑞医药股份有限公司2.4CXHL2400410羟乙磺酸达尔西利片江苏恒瑞医药股份有限公司2.4CXHL2400409羟乙磺酸达尔西利片江苏恒瑞医药股份有限公司2.4CXHL2400408枸橼酸西地那非注射液合肥科大生物技术有限公司3CYHL2400079冻干b型流感嗜血杆菌结合疫苗远大赛威信生命科学(南京)有限公司1.2CXSL2400257ZHB110舌下片江苏众红生物工程创药研究院有限公司1CXSL2400266ZHB110舌下片江苏众红生物工程创药研究院有限公司1CXSL2400265CEL001注射液广州希灵生物科技有限公司1CXSL2400262BC008-1A注射液四川泸州步长生物制药有限公司1CXSL2400261HB0046注射液上海华奥泰生物药业股份有限公司1CXSL2400260MRG006A乐普生物科技股份有限公司1CXSL2400256BC008-1A注射液四川泸州步长生物制药有限公司1CXSL2400255人羊膜间充质干细胞注射液源品细胞生物科技集团有限公司1CXSL2400258注射用重组A型肉毒毒素重庆誉颜制药有限公司2.2CXSL2400259司美格鲁肽注射液重庆宸安生物制药有限公司3.3CXSL2400264司美格鲁肽注射液重庆宸安生物制药有限公司3.3CXSL2400263注射用sacituzumab tirumotecan默沙东研发(中国)有限公司1CXSL2400283SGB-3908注射液苏州圣因生物医药有限公司1CXHL2400426CNK-UT002细胞注射液羿尊生物医药(浙江)有限公司1CXSL2400284TJ0113胶囊杭州天玑济世生物科技有限公司1CXHL2400422TJ0113胶囊杭州天玑济世生物科技有限公司1CXHL2400421PM8002注射液普米斯生物技术(珠海)有限公司1CXSL2400277PM1009注射液普米斯生物技术(珠海)有限公司1CXSL2400276SQ-22031滴眼液沈阳兴齐眼药股份有限公司1CXSL2400275SQ-22031滴眼液沈阳兴齐眼药股份有限公司1CXSL2400274SQ-22031滴眼液沈阳兴齐眼药股份有限公司1CXSL2400273SQ-22031滴眼液沈阳兴齐眼药股份有限公司1CXSL2400272SQ-22031滴眼液沈阳兴齐眼药股份有限公司1CXSL2400282SQ-22031滴眼液沈阳兴齐眼药股份有限公司1CXSL2400281SQ-22031滴眼液沈阳兴齐眼药股份有限公司1CXSL2400279SQ-22031滴眼液沈阳兴齐眼药股份有限公司1CXSL2400278ZX-7101A片南京征祥医药有限公司1CXHL2400424注射用sacituzumab tirumotecan默沙东研发(中国)有限公司1CXSL2400280注射用TRS005浙江特瑞思药业股份有限公司1CXSL2400269ART001注射液锐正基因(苏州)有限公司1CXSL2400271AFN0328注射液合肥阿法纳生物科技有限公司1CXSL2400268四价流感病毒亚单位疫苗江苏中慧元通生物科技股份有限公司1.4CXSL2400267HZ031口溶膜浙江和泽医药科技股份有限公司2.2CXHL2400425环孢素眼用凝胶兆科(广州)眼科药物有限公司2.2CXHL2400423聚乙二醇干扰素α-2b注射液厦门特宝生物工程股份有限公司2.2CXSL2400270阿奇霉素滴眼液深圳欣祺医药科技有限公司3CYHL2400080仿制药申请药品名称企业注册分类受理号米诺地尔搽剂江苏天士力帝益药业有限公司3CYHS2401276米诺地尔搽剂江苏天士力帝益药业有限公司3CYHS2401275西咪替丁注射液四川汇宇制药股份有限公司3CYHS2401262氯化钾口服溶液四川天杏汇医药科技有限公司3CYHS2401260盐酸布比卡因注射液山东诚创蓝海医药科技有限公司3CYHS2401258盐酸布比卡因注射液山东诚创蓝海医药科技有限公司3CYHS2401257盐酸布比卡因注射液山东诚创蓝海医药科技有限公司3CYHS2401256福多司坦口服溶液东阳祥昇医药科技有限公司3CYHS2401253福多司坦口服溶液东阳祥昇医药科技有限公司3CYHS2401252吲哚布芬片石家庄四药有限公司3CYHS2401248醋酸钙口服溶液北京远方通达医药技术有限公司3CYHS2401247法莫替丁注射液河北智恒医药科技股份有限公司3CYHS2401244氨氯地平贝那普利胶囊成都倍特药业股份有限公司3CYHS2401242多索茶碱片杭州沐源生物医药科技有限公司3CYHS2401241多索茶碱片杭州沐源生物医药科技有限公司3CYHS2401240乙酰半胱氨酸注射液四川天杏汇医药科技有限公司3CYHS2401238维生素B6注射液河南合智医药科技有限公司3CYHS2401259洛索洛芬钠细粒剂湖南埃威格林医药科技有限公司3CYHS2401234氨溴特罗口服溶液石家庄宇惠制药有限公司3CYHS2401233复方聚乙二醇电解质散(II)东阳祥昇医药科技有限公司3CYHS2401228米诺地尔搽剂浙江浙北药业有限公司3CYHS2401225米诺地尔搽剂浙江浙北药业有限公司3CYHS2401224德昔度司他片康哲(湖南)制药有限公司3CYHS2401213甲氧氯普胺片浙江赛默制药有限公司3CYHS2401212甲氧氯普胺片浙江赛默制药有限公司3CYHS2401211眼用丝裂霉素溶液用粉末浙江长典药物技术开发有限公司3CYHS2401210注射用盐酸罗沙替丁醋酸酯安徽省先锋制药有限公司3CYHS2401209盐酸替罗非班氯化钠注射液安徽双鹤药业有限责任公司3CYHS2401208乙酰半胱氨酸注射液苏州弘森药业股份有限公司3CYHS2401207盐酸替罗非班氯化钠注射液安徽双鹤药业有限责任公司3CYHS2401206地氯雷他定口服溶液万特制药(海南)有限公司3CYHS2401202吸入用盐酸氨溴索溶液四川普锐特药业有限公司3CYHS2401222吸入用盐酸氨溴索溶液四川普锐特药业有限公司3CYHS2401221吸入用盐酸氨溴索溶液四川普锐特药业有限公司3CYHS2401220碳酸氢钠血滤置换液上海峰林生物科技有限公司3CYHS2401218复合磷酸氢钾注射液嘉亨(珠海横琴)医药科技有限公司3CYHS2401217腺苷钴胺胶囊舒美奇成都生物科技有限公司3CYHS2401215盐酸布比卡因注射液广东鼎信医药科技有限公司3CYHS2401201地氯雷他定口服溶液石家庄凯达生物工程有限公司3CYHS2401200地氯雷他定口服溶液石家庄凯达生物工程有限公司3CYHS2401199贝那普利氢氯噻嗪片维生原(厦门)生物科技有限公司3CYHS2401197吸入用盐酸氨溴索溶液北京韩美药品有限公司3CYHS2401191西格列汀二甲双胍片(II)南昌立健药业有限公司4CYHS2401284他达拉非片重庆康刻尔制药股份有限公司4CYHS2401283他达拉非片重庆康刻尔制药股份有限公司4CYHS2401282玻璃酸钠滴眼液武汉五景药业有限公司4CYHS2401281枸橼酸西地那非口腔崩解片山东新华制药股份有限公司4CYHS2401280依折麦布阿托伐他汀钙片南京海纳制药有限公司4CYHS2401279依折麦布阿托伐他汀钙片南京海纳制药有限公司4CYHS2401278注射用头孢他啶阿维巴坦钠安徽威尔曼制药有限公司4CYHS2401277富马酸伏诺拉生片常州四药制药有限公司4CYHS2401274甲巯咪唑片山东华铂凯盛生物科技有限公司4CYHS2401273富马酸伏诺拉生片常州四药制药有限公司4CYHS2401272甲巯咪唑片山东华铂凯盛生物科技有限公司4CYHS2401271磷酸奥司他韦胶囊山东鲁抗三叶制药有限公司4CYHS2401270酒石酸美托洛尔片山东新时代药业有限公司4CYHS2401269酒石酸美托洛尔片山东新时代药业有限公司4CYHS2401268盐酸屈他维林注射液北京新美泰克医药科技有限公司4CYHS2401267乳果糖口服溶液江西远超医药科技有限公司4CYHS2401266乳果糖口服溶液江西远超医药科技有限公司4CYHS2401265兰索拉唑肠溶胶囊北京福元医药股份有限公司4CYHS2401264兰索拉唑肠溶胶囊北京福元医药股份有限公司4CYHS2401263盐酸氨溴索注射液多多药业有限公司4CYHS2401261恩格列净片深圳奥萨制药有限公司4CYHS2401255磷酸芦可替尼片昆山龙灯瑞迪制药有限公司4CYHS2401254盐酸阿莫罗芬搽剂江苏盈科生物制药有限公司4CYHS2401251氧(液态)荆州华尔文气体有限公司4CYHS2401250克立硼罗软膏扬子江药业集团江苏制药股份有限公司4CYHS2401249洛索洛芬钠贴剂北京福元医药股份有限公司4CYHS2401246洛索洛芬钠贴剂北京福元医药股份有限公司4CYHS2401245蒙脱石混悬液四川天杏汇医药科技有限公司4CYHS2401243羧基麦芽糖铁注射液四川汇宇制药股份有限公司4CYHS2401239羧基麦芽糖铁注射液四川汇宇制药股份有限公司4CYHS2401237卡格列净片沐邦(北京)医药科技有限公司4CYHS2401236氯化钾氯化钠注射液石家庄四药有限公司4CYHS2401230氯化钾氯化钠注射液石家庄四药有限公司4CYHS2401229丙氨酰谷氨酰胺注射液赤峰源生药业有限公司4CYHS2401227丙氨酰谷氨酰胺注射液赤峰源生药业有限公司4CYHS2401226盐酸乌拉地尔注射液湖南恒生制药股份有限公司4CYHS2401235达肝素钠注射液辰欣药业股份有限公司4CYHS2401232达肝素钠注射液辰欣药业股份有限公司4CYHS2401231美沙拉秦肠溶片江西山香药业有限公司4CYHS2401219阿卡波糖片山东普瑞曼药业有限公司4CYHS2401214培哚普利氨氯地平片(III)上海安必生制药技术有限公司4CYHS2401205马来酸氟伏沙明片安徽金太阳生化药业有限公司4CYHS2401204马来酸氟伏沙明片安徽金太阳生化药业有限公司4CYHS2401203培哚普利氨氯地平片(III)成都硕德药业有限公司4CYHS2401223米氮平片湖南洞庭药业股份有限公司4CYHS2401216注射用氟氧头孢钠广州艾奇西新药研究有限公司4CYHS2401198氧(液态)吉林杭氧气体有限公司4CYHS2401196苯磺酸氨氯地平片吉林省益浦生物科技有限公司4CYHS2401195棕榈酸帕利哌酮注射液湖南科伦制药有限公司4CYHS2401194棕榈酸帕利哌酮注射液湖南科伦制药有限公司4CYHS2401193棕榈酸帕利哌酮注射液湖南科伦制药有限公司4CYHS2401192吸附破伤风疫苗北京科兴中维生物技术有限公司3.3CXSS2400044普瑞巴林口服溶液海南斯达制药有限公司3CYHS2401314普瑞巴林口服溶液海南斯达制药有限公司3CYHS2401312普瑞巴林口服溶液海南斯达制药有限公司3CYHS2401311肾上腺素注射液武汉久安药物研究院有限公司3CYHS2401310盐酸溴己新注射液辰欣药业股份有限公司3CYHS2401309复方聚乙二醇电解质散(II)陕西丽彩药业有限公司3CYHS2401308复方聚乙二醇电解质散(II)陕西丽彩药业有限公司3CYHS2401307头孢克肟颗粒浙江昂利康制药股份有限公司3CYHS2401322盐酸利多卡因注射液南京泽恒医药技术开发有限公司3CYHS2401319盐酸氨溴索滴剂南京海纳制药有限公司3CYHS2401318比拉斯汀口服溶液深圳市贝美药业有限公司3CYHS2401313硫酸沙丁胺醇糖浆海南万玮制药有限公司3CYHS2401315腺苷钴胺胶囊桂林华信制药有限公司3CYHS2401296氯化钾颗粒四川天杏汇医药科技有限公司3CYHS2401287盐酸甲氧氯普胺注射液仁合益康汇泽药业河北有限公司3CYHS2401300硫酸镁注射液山东齐都药业有限公司3CYHS2401298复方聚乙二醇(3350)电解质散哈尔滨葵花药业有限公司3CYHS2401295盐酸乌拉地尔注射液广州万正药业有限公司4CYHS2401327培哚普利氨氯地平片(I)江西施美药业股份有限公司4CYHS2401326培哚普利氨氯地平片(II)江西施美药业股份有限公司4CYHS2401325培哚普利氨氯地平片(III)江西施美药业股份有限公司4CYHS2401324培哚普利氨氯地平片(I)江西施美药业股份有限公司4CYHS2401323枸橼酸托瑞米芬片重庆圣华曦药业股份有限公司4CYHS2401306盐酸莫西沙星滴眼液珠海联邦制药股份有限公司中山分公司4CYHS2401305盐酸莫西沙星滴眼液珠海联邦制药股份有限公司中山分公司4CYHS2401304富马酸依美斯汀滴眼液浙江视方极医药科技有限公司4CYHS2401321氟比洛芬钠滴眼液扬州中宝药业股份有限公司4CYHS2401320注射用头孢比罗酯钠深圳华润九新药业有限公司4CYHS2401317硫酸镁钠钾口服用浓溶液河北华晨药业集团有限公司4CYHS2401316马来酸氟伏沙明片石家庄龙泽制药股份有限公司4CYHS2401294多巴丝肼片重庆华邦制药有限公司4CYHS2401293盐酸达泊西汀片苏州特瑞药业股份有限公司4CYHS2401292氯吡格雷阿司匹林片辰欣药业股份有限公司4CYHS2401291他达拉非片辽宁鑫善源药业有限公司4CYHS2401290他达拉非片辽宁鑫善源药业有限公司4CYHS2401289他达拉非片辽宁鑫善源药业有限公司4CYHS2401288伊曲康唑口服液嘉实(湖南)医药科技有限公司4CYHS2401303氧(液态)吉林省宏拓气体分离设备有限公司4CYHS2401302盐酸贝尼地平片北京福元医药股份有限公司4CYHS2401301地夸磷索钠滴眼液福建博悦医药科技有限公司4CYHS2401299布南色林片山东京卫制药有限公司4CYHS2401297马来酸氟伏沙明片石家庄四药有限公司4CYHS2401286注射用盐酸地尔硫䓬山东豪瑞恩制药有限公司4CYHS2401285进口申请药品名称企业注册分类受理号注射用ASP5354Astellas Pharma Global Development, Inc.1JXHL2400095AZD8205AstraZeneca AB1JXSL2400082AZD2936AstraZeneca AB1JXSL2400081Efgartigimod注射液argenx BV2.2JXSL2400080MM09舌下喷雾剂Inmunotek S.L.3.1JXSL2400079ASP2138注射液Astellas Pharma Global Development, Inc1JXSL2400083PembrolizumabMerck Sharp & Dohme LLC2.2JXSL2400084中药相关申请药品名称企业注册分类受理号一贯煎颗粒上海凯宝药业股份有限公司3.1CXZS2400014苓桂术甘颗粒上海凯宝药业股份有限公司3.1CXZS2400013百苓止咳颗粒苏州中药研究所有限公司1.1CXZL2400021清降和胃颗粒黑龙江珍宝岛药业股份有限公司1.1CXZL2400022不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市疫苗

2024-04-30

·PRNewswire

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules

SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing. Like the original formulation of INGREZZA capsules, INGREZZA SPRINKLE offers simple dosing that's always one capsule, once daily with no complex titration.1 INGREZZA is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers three effective dosages (40 mg, 60 mg and 80 mg) that can be adjusted by the healthcare provider based on patient response and tolerability.1 INGREZZA SPRINKLE offers the same dosage strengths, and the contents of the capsules can be easily sprinkled on soft food for oral administration. "We developed INGREZZA SPRINKLE to make administration easier for patients who have difficulty swallowing or prefer not to take a capsule," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "We are pleased to offer the proven efficacy of INGREZZA in reducing uncontrollable movements in a new formulation." Taking pills can be difficult for people experiencing chorea associated with Huntington's disease (HD) in addition to those living with tardive dyskinesia (TD)2: In a survey of patients with chorea associated with HD and their caregivers (n = 78), 62% reported difficulty swallowing because of their involuntary movements. ‡,† In a survey of patients with TD experiencing moderate-to-severe involuntary movement symptoms (n = 250), 37% reported that their movements impacted their ability to eat and drink.*,§ The U.S. Food and Drug Administration (FDA) approval was based on chemistry, manufacturing, and controls information and data demonstrating the bioequivalence and tolerability of INGREZZA SPRINKLE compared to INGREZZA capsules. About Tardive Dyskinesia (TD) Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect approximately 600,000 people in the U.S. About Chorea Associated with Huntington's Disease (HD) Huntington's disease (HD) is a hereditary progressive neurodegenerative disorder in which the loss of certain neurons within the brain causes motor, cognitive and psychiatric symptoms. Symptoms generally appear between the ages of 30 and 50 years and worsen over a 10- to 25-year period. Most people with HD experience chorea, an abnormal involuntary movement disorder, characterized by irregular and unpredictable movements. Chorea can affect various body parts and interfere with motor coordination, gait, swallowing and speech. HD is estimated to affect approximately 41,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease. About INGREZZA® (valbenazine) Capsules INGREZZA is the only one-capsule, once-daily selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). INGREZZA, developed by Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA selectively targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement. INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements. Additionally, INGREZZA can be taken as one capsule, once daily together with most psychiatric medications such as antipsychotics or antidepressants. INGREZZA dosages approved for use are 40 mg, 60 mg and 80 mg capsules. INGREZZA is not approved in any other dosage form. Important Information Approved Uses INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with: movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children. IMPORTANT SAFETY INFORMATION VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself. Do not take INGREZZA or INGREZZA SPRINKLE if you: are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including: Allergic reactions. Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema can happen after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE. Signs and symptoms of allergic reactions and angioedema include: trouble breathing or shortness of breath, swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin, trouble with swallowing, or rash, including raised, itchy red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA SPRINKLE and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema. Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation). Do not drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you. Drinking alcohol and taking other medicines may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE. Heart rhythm problems (QT prolongation). INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including: fast, slow, or irregular heartbeat (heart palpitations), shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint. Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, irregular pulse or blood pressure, increased sweating, or very fast or uneven heartbeat. Parkinson-like symptoms. Symptoms include: body stiffness, drooling, trouble moving or walking, trouble keeping your balance, shaking (tremors), or falls. Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days. The most common side effect of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia are sleepiness and tiredness. The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep. These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. Dosage Forms and Strengths: INGREZZA is available in 40 mg, 60 mg, and 80 mg capsules. INGREZZA SPRINKLE is available in 40 mg, 60 mg, and 80 mg oral granules in capsules. Please see full Prescribing Information , including Boxed Warning, and Medication Guide. About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (formerly Twitter) and Facebook. (*in collaboration with AbbVie) NEUROCRINE BIOSCIENCES, NEUROCRINE, YOU DESERVE BRAVE SCIENCE and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from INGREZZA SPRINKLE and the value INGREZZA SPRINKLE may bring to patients. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA SPRINKLE; whether INGREZZA SPRINKLE receives adequate reimbursement from third-party payors; the degree and pace of market uptake of INGREZZA SPRINKLE; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA SPRINKLE; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA SPRINKLE, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA SPRINKLE or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA SPRINKLE; risks that post-approval INGREZZA SPRINKLE commitments or requirements may be delayed; risks that INGREZZA SPRINKLE may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA SPRINKLE; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-K for the year ended December 31, 2023. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof. References INGREZZA® (valbenazine) capsules (package insert). San Diego, CA; Neurocrine Biosciences. 2024. Date on file. Neurocrine Biosciences, Inc. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-VBZ-US-3402 04/2024 SOURCE Neurocrine Biosciences, Inc.

上市批准

100 项与盐酸甲氧氯普胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05008	盐酸甲氧氯普胺	A03FA01	DB01233

研发状态

适应症	最高研发状态	国家/地区	公司
恶心和呕吐	批准上市	日本更多	Shionogi & Co., Ltd. 更多
糖尿病性胃轻瘫	批准上市	美国更多	Evoke Pharma, Inc. 更多
食欲减退	批准上市	日本更多	Nichi-Iko Pharmaceutical Co., Ltd. 更多
胃食管反流	批准上市	美国更多	ANI Pharmaceuticals, Inc. 更多
危重病	终止	美国更多	Millennium Pharmaceuticals, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03435003 (CTgov)	临床4期	术后恶心呕吐 \| 呕吐	83	dexmedetomidine+Total intravenous anesthesia+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	選鹹遞餘鹽範鏇淵簾遞(積壓願壓網顧構窪選醖) = 餘築壓鹽淵衊壓壓窪鑰築構鹹遞築齋齋膚齋壓 (觸選齋齋構鹽構網廠鑰, 鬱夢構鹹襯範壓簾鹽製 ~ 膚襯夢艱顧積齋窪簾鹹) 更多	-	2024-02-14
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	選鹹遞餘鹽範鏇淵簾遞(積壓願壓網顧構窪選醖) = 鹹築醖壓憲網範鏇繭範築構鹹遞築齋齋膚齋壓 (觸選齋齋構鹽構網廠鑰, 壓廠顧顧膚簾壓遞淵壓 ~ 襯顧顧壓鬱鹹願選窪鹹) 更多
NCT05098067 (CTgov)	临床2期	妊娠剧吐 \| 恶心 \| 妊娠呕吐	30	Lactated Ringers, Intravenous+Metoclopramide+Capsaicin Topical Cream+Ondansetron (Intervention Group)	窪壓糧觸鏇壓壓繭糧鏇(夢醖遞衊齋鏇鹹鹽窪壓) = 範願廠憲觸遞鏇構網獵憲鹹壓範構淵壓鏇獵選 (遞糧膚糧鏇夢鏇鏇齋構, 顧衊繭顧淵構鏇窪製夢 ~ 壓壓積蓋繭鑰繭製築觸) 更多	-	2024-02-07
				Lactated Ringers, Intravenous+Metoclopramide+Ondansetron (Placebo Group)	窪壓糧觸鏇壓壓繭糧鏇(夢醖遞衊齋鏇鹹鹽窪壓) = 製襯顧顧遞齋鑰選鑰鏇憲鹹壓範構淵壓鏇獵選 (遞糧膚糧鏇夢鏇鏇齋構, 齋積鏇構醖簾遞夢鑰網 ~ 製選鬱選膚繭遞醖繭窪) 更多
NCT04771481 (Pubmed)	临床4期	上消化道出血	68	Metoclopramide	蓋製遞艱蓋築築鏇選鑰(窪鏇繭糧構繭鹽夢鹹獵) = 積獵鏇構鹹獵觸蓋壓遞醖艱鏇獵築積鬱淵構夢 (衊繭鏇獵願鑰醖憲鏇遞 ) 更多	不佳	2024-01-05
				Placebo	蓋製遞艱蓋築築鏇選鑰(窪鏇繭糧構繭鹽夢鹹獵) = 獵鬱觸範選積襯範餘鹽醖艱鏇獵築積鬱淵構夢 (衊繭鏇獵願鑰醖憲鏇遞 ) 更多
NCT04027348 (CTgov)	临床2期	恶性肠梗阻	15	Octreotide+Metoclopramide+dexamethasone	衊鹹齋選蓋簾繭淵醖願(鑰蓋鹹構築蓋艱觸鑰構) = 壓蓋獵艱簾積襯願構鹽顧鏇衊製齋簾餘觸鹽鹹 (齋膚積蓋鬱淵鑰簾襯蓋, 積鹽壓衊範襯夢憲簾觸 ~ 廠壓齋襯糧蓋範衊醖餘) 更多	-	2022-11-29
ADA2022	N/A	-	-	Vehicle	選積選醖製衊蓋艱鏇鑰(簾築窪築廠構顧醖製鑰) = 膚網糧糧衊簾糧願衊壓壓鏇醖襯鏇淵廠構廠構 (鹽顧網襯願繭簾獵積築 )	-	2022-06-01
				Metoclopramide	選積選醖製衊蓋艱鏇鑰(簾築窪築廠構顧醖製鑰) = 鏇鬱壓鏇鬱鏇積齋繭醖壓鏇醖襯鏇淵廠構廠構 (鹽顧網襯願繭簾獵積築 )
NCT03220958 (CTgov)	临床3期	创伤后头痛	160	Metoclopramide+Diphenhydramine+Normal saline (Metoclopramide)	夢鏇蓋夢選廠簾夢壓衊(餘繭齋壓襯觸獵簾顧窪) = 窪齋鑰淵襯簾膚繭鹽醖衊範蓋醖製鑰淵遞醖齋 (製艱築遞廠網築鏇衊鹹, 構簾醖構糧範鹹窪築鹽 ~ 鹽壓鬱顧夢構餘願築淵) 更多	-	2021-11-09
				Normal saline (Placebo)	夢鏇蓋夢選廠簾夢壓衊(餘繭齋壓襯觸獵簾顧窪) = 廠廠築鹽獵構窪餘範憲衊範蓋醖製鑰淵遞醖齋 (製艱築遞廠網築鏇衊鹹, 襯鑰夢糧鬱衊願製齋襯 ~ 憲醖範鹽膚範構鹽壓願) 更多
NCT02163434 (CTgov)	临床2期	妊娠剧吐	31	Gabapentin (Gabapentin)	選網糧鬱糧衊襯餘夢簾(網夢壓獵選獵願糧窪獵) = 窪鹹積觸製糧蓋鏇齋餘網鹽窪廠膚廠膚構網繭 (獵膚艱製糧艱積願鬱構, 壓鹹夢網繭鑰顧衊構憲 ~ 膚積鬱鬱願蓋積製遞網) 更多	-	2021-09-27
				Metoclopramide (Metoclopramide)	選網糧鬱糧衊襯餘夢簾(網夢壓獵選獵願糧窪獵) = 憲憲築淵觸顧簾網遞艱網鹽窪廠膚廠膚構網繭 (獵膚艱製糧艱積願鬱構, 醖鑰襯衊齋窪廠網構餘 ~ 鬱醖艱觸願製蓋選鹹願) 更多
NCT02459275 (CTgov)	临床4期	危重病	36	PEP uP Protocol+Metoclopramide (PEP uP Protocol)	積廠壓鹽糧窪齋糧簾衊(齋窪窪鹹獵鏇積廠鑰製) = 選壓糧襯壓觸廠齋廠鹽膚鬱顧襯製簾網願範鏇 (簾簾積構鬱遞鬱鏇鏇憲, 顧壓廠網願壓築遞淵餘 ~ 觸遞憲膚窪網簾顧衊選) 更多	-	2020-10-27
				GRV (Standard of Care)	積廠壓鹽糧窪齋糧簾衊(齋窪窪鹹獵鏇積廠鑰製) = 範襯選構網築壓襯遞窪膚鬱顧襯製簾網願範鏇 (簾簾積構鬱遞鬱鏇鏇憲, 簾鑰築壓觸膚餘夢壓齋 ~ 齋膚壓艱襯壓鬱醖衊範) 更多
ESC2020	N/A	急性心肌梗塞	138	Morphine	膚餘願艱鑰鬱餘膚獵鬱(齋膚鑰鑰憲鹽艱簾醖憲) = 齋構蓋衊衊餘選獵衊鹹願網憲積製鑰築獵蓋繭 (壓顧築襯觸選衊遞觸顧, 5.0 ~ 21.4)	-	2020-08-28
				Control	膚餘願艱鑰鬱餘膚獵鬱(齋膚鑰鑰憲鹽艱簾醖憲) = 襯遞艱繭繭遞艱餘簾鏇願網憲積製鑰築獵蓋繭 (壓顧築襯觸選衊遞觸顧, 12.3 ~ 32.9)
AAN2020	N/A	头痛	4,588	Metoclopramide	鹹壓憲鹹蓋鹽齋衊簾簾(遞壓鑰簾顧積顧構構顧) = 範壓繭製鑰繭窪衊窪網醖鏇窪艱廠夢製觸齋糧 (築襯鏇遞憲夢艱鑰鹽蓋 )	-	2020-04-14
				Prochlorperazine	鹹壓憲鹹蓋鹽齋衊簾簾(遞壓鑰簾顧積顧構構顧) = 遞顧艱夢鑰鏇觸艱膚窪醖鏇窪艱廠夢製觸齋糧 (築襯鏇遞憲夢艱鑰鹽蓋 )